Investing.com - Financial Markets Worldwide

Kiromic Biopharma Inc (KRBPQ)

OTC Markets
Currency in USD
0.004
0.000(0.00%)
Delayed Data·
KRBPQ Scorecard
Full Analysis
Stock generally trades with high price volatility
Trading near 52-week Low
KRBPQ is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
0.0040.004
52 wk Range
0.0042.100
Key Statistics
Edit
Prev. Close
0.004
Open
0.004
Day's Range
0.004-0.004
52 wk Range
0.004-2.1
Volume
-
Average Volume (3m)
6.99K
1-Year Change
-99.82%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KRBPQ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 15
Suffers from weak gross profit margins
Unlock InvestingPro

Kiromic Biopharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Kiromic Biopharma Inc Company Profile

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company’s lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; Procel, which is in clinical trial in combination with low-dose radiation to treat PD-L1 positive solid malignancies; ALEXIS-ISO-1, which is in clinical trial to evaluate Isocel in patients with Mesothelin Isoform 2 positive solid malignancies; and ALEXIS-PRO-1, which is in clinical trial to evaluate Procel in patients with PD-L1 positive solid malignancies. It has a license agreement with Longwood University. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. On March 21, 2025, Kiromic BioPharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
44
Market
United States

Compare KRBPQ to Peers and Sector

Metrics to compare
KRBPQ
Peers
Sector
Relationship
P/E Ratio
0.0x−4.3x−0.6x
PEG Ratio
0.000.030.00
Price/Book
0.0x2.5x2.6x
Price / LTM Sales
0.0x8.6x3.3x
Upside (Analyst Target)
0.0%150.0%39.0%
Fair Value Upside
Unlock−0.6%4.9%Unlock

Earnings

Latest Release
Feb 14, 2025
EPS / Forecast
13.13 / --
Revenue / Forecast
-- / --
EPS Revisions
a
a
Unlock
Last 90 days

KRBPQ Income Statement

FAQ

What Stock Exchange Does Kiromic Trade On?

Kiromic is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Kiromic?

The stock symbol for Kiromic is "KRBPQ."

What Is the Kiromic Market Cap?

As of today, Kiromic market cap is 6.28K.

What Is Kiromic's Earnings Per Share (TTM)?

The Kiromic EPS (TTM) is -3.17.

From a Technical Analysis Perspective, Is KRBPQ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Kiromic Stock Split?

Kiromic has split 1 times.

How Many Employees Does Kiromic Have?

Kiromic has 44 employees.

What is the current trading status of Kiromic (KRBPQ)?

As of 26 Aug 2025, Kiromic (KRBPQ) is trading at a price of 0.00, with a previous close of 0.00. The stock has fluctuated within a day range of 0.00 to 0.00, while its 52-week range spans from 0.00 to 2.10.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.